Zydus Cadila receives final approval from USFDA for Apremilast Tablets

Zydus Cadila receives final approval from USFDA for Apremilast Tablets Ahmedabad, India, 24 September, 2021 Zydus Cadila ’s U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval from the USFDA to market Apremilast Tablets in the strength s of 10 mg, 20 mg, 3 0 mg (US RLD: Otezla® Tablets). Zydus’ Apremilast Tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 323 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcar e therapies. The group employs over 23 000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗